RJA
ALPN

Raymond James & Associates’s Alpine Immune Sciences Inc ALPN Stock Holding History

Raymond James & Associates’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,641
Closed -$66K – 3739
2019
Q2 		$66K Buy
15,641
+1,897
+14% +$11K ﹤0.01% 3473
2019
Q1 		$94K Buy
+13,744
New +$85.7K ﹤0.01% 3400

Other funds holding ALPN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James & Associates's ALPN Position: Q3 2019 in Review

Raymond James & Associates sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2019, closing a stake of 15,641 shares — an estimated $66K sold.

Raymond James & Associates first reported a position in ALPN in Q1 2019 and held it in 2 quarters. The position peaked at $94K in Q1 2019. 21 funds tracked by Wall St. Rank hold ALPN as of Q3 2019.

  • Raymond James & Associates reported no remaining Alpine Immune Sciences Inc position as of Q3 2019 after selling out during the quarter.
  • Raymond James & Associates sold 15,641 Alpine Immune Sciences Inc shares in Q3 2019, an estimated $66K.
  • Raymond James & Associates first reported a position in Alpine Immune Sciences Inc in Q1 2019 and held it in 2 quarters.
  • Raymond James & Associates's Alpine Immune Sciences Inc position peaked at $94K in Q1 2019.
  • 21 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2019.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.